Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

Not specified

Study Completion Date

December 31, 2005

Conditions
HIV InfectionsHIV Seronegativity
Interventions
BIOLOGICAL

ALVAC(2)120(B,MN)GNP (vCP1452)

Trial Locations (13)

10021

NY Blood Ctr./Union Square CRS, New York

14642

Univ. of Rochester HVTN CRS, Rochester

35294

Alabama Vaccine CRS, Birmingham

37232

Vanderbilt Vaccine CRS, Nashville

63110

Saint Louis Univ Health Sciences Ctr, St Louis

94102

San Francisco Vaccine and Prevention CRS, San Francisco

98109

FHCRC/UW Vaccine CRS, Seattle

Unknown

UCSF, Gen. Clinical Research Ctr., Mt. Zion Hosp., San Francisco

Project Brave HIV Vaccine CRS, Baltimore

Infectious Diseases Physicians, Inc., Annandale

02115

Brigham and Women's Hosp. CRS, Boston

Fenway Community Health Clinical Research Site (FCHCRS), Boston

02906

Miriam Hospital's HVTU, Providence

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00027261 - Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults | Biotech Hunter | Biotech Hunter